Overview

HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Status:
RECRUITING

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

Summary

This is a single-arm exploratory clinical study to evaluate the efficacy and safety of HAIC in combination with Sintilimab and Donafenib in patients with BCLC-C stage who have not received prior systemic therapy

Phase:

PHASE2

Details

Lead Sponsor:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology